• Active Biotech AB, of Lund, Sweden, and Teva Pharmaceutical Industries Ltd., of Jerusalem, reported that following a meeting with the FDA, Teva determined it would be premature to file a new drug application for multiple sclerosis drug laquinimod, and that the FDA has offered to work with Teva to determine the best design for conducting an additional trial.• Aslan Pharmaceuticals Pte Ltd., of Singapore, is partnering with Bristol-Myers Squibb Co., of New York, to accelerate the development of BMS